Company profile: Cytognos
1.1 - Company Overview
Company description
- Provider of flow cytometry solutions for blood cancer diagnosis, minimal residual disease detection, and immune monitoring research. Offers Infinicyt software for multicolor data integration and analysis; EuroFlow 8-color antibody panels; OC515 dye; APC-C750 fluorochrome; and Next Generation Flow immunophenotyping protocols.
Products and services
- Infinicyt: Multicolor-compatible software that integrates and analyzes complex flow cytometry datasets, supporting various cytometer file formats for cohesive data comparison and interpretation in blood disease research
- Next Generation Flow: 8-color protocols architected for immunophenotyping in hemato-oncology, employing defined tubes to deliver detailed leukocyte population analysis for precise characterization in blood cancer diagnostic studies
- EuroFlow Antibody Panels: 8-color premixed immunostaining cocktails engineered for diagnosing and monitoring hematological and immunological disorders, streamlining panel selection and consistency across multicolor flow cytometry experiments
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cytognos
IGM Biosciences
HQ: United States
Website
- Description: Provider of a proprietary, clinical-stage IgM antibody platform developing engineered IgM therapeutics for cancer, autoimmune and inflammatory diseases. Pipeline includes imvotamab (CD20xCD3) for autoimmune diseases, aplitabart (DR5) for colorectal cancer, and IGM-2644 (CD38xCD3) for autoimmune diseases, all in early trials. Also offers an expanded access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IGM Biosciences company profile →
Sevion Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery, development, and acquisition of innovative therapeutic product candidates for cancer and immunological diseases, advancing a pipeline of proprietary and partnered candidates leveraging unique antibody technology platforms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sevion Therapeutics company profile →
Lengo Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions focused on discovering and developing cancer treatments, including AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis and gastrointestinal stromal tumors with PDGFRA exon 18 mutations. Offers clinical trials, a U.S. patient support program for access and affordability, and a scientific platform to develop highly selective medicines for mast cell disorders and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lengo Therapeutics company profile →
Lymphatica Medtech
HQ: Switzerland
Website
- Description: Provider of medical device development, creating a minimally invasive solution for chronic lymphedema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lymphatica Medtech company profile →
Scorpion Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision oncology therapeutics, developing small-molecule inhibitors targeting the H1047X-mutant PI3Kα in solid tumors (STX-H1047-PI3Kα) and exon 20 insertion mutations in EGFR driving non-small cell lung cancer (STX-EGFR-EXON20).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scorpion Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cytognos
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cytognos
2.2 - Growth funds investing in similar companies to Cytognos
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cytognos
4.2 - Public trading comparable groups for Cytognos
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →